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KADISH, A., ET AL.: Management of Nonsustained Ventricular Tachycardia Guided By Electrophysiologi-
cal Testing. Two hundred eighty patients with spontaneous nonsusfained ventricular tachycardia were
treated based on the results of electrophysioJogical testing. Seventy-nine patients had no evidence 0/
structural heart disease, 134 had coronary artery disease, 43 had idiopathic dilated cardiomyopathy,
and 24 patients had miscellaneous types of heart disease. Sustained monomorphic ventricular tachycar-
dia was induced during electrophysiological testing in the drug free state in 52 of 280 patients fl9%).
Ventricular tachycardia was induced more frequently in patients with coronary artery disease {32%} than
in any of the other groups (P < 0.001}. The patients with inducible sustained monomorphic ventricular
tachycardia underwent a mean of 1.9 ± 1.3 drug trials. Twenty-five patients had the induction of ventricu-
lar tachycardia suppressed by pharmacological therapy and were treated with the drug judged to be
effective during electropharmacological testing. Twenty-seven patients continued to have inducible sus-
tained monomorphic ventricular tachycardia despite antiarrhythmic therapy and were discharged on
the drug that made induced ventricular tachycardia best tolerated. Forty-five of 280 patients (16.1%)
died during a mean follow-up period of 19.6 ± 14.4 months, There were 15 sudden cardiac deaths, 21
nonsudden cardiac deaths, 6 noncardiac deaths, and 3 deaths that could not be classified. Sudden
cardiac death mortality was lowest in the patients without structural heart disease (0% at 2 years),
intermediate in the patients with coronary artery disease and miscellaneous heart disease (4% al 2 years),
and highest in the patients with idiopathic dilated cardiomyopathy (13% at 2 years; P < 0.01 for pairwise
comparisons). No patient treated with a drug that had suppressed the induction of sustained ventricular
tachycardia died suddenly during the follow-up period whereas four of 27 patients who were discharged
on "ineffective antiarrhythmic drugs" and 11 of 228 patients without inducible sustained ventricular
tachycardia experienced sudden cardiac death during the foUow-up period. By muJtivariate analysis,
ejection fraction and inducibJe ventricular tachycardia during the predischarge eiectrophysiological test
were independent predictors of sudden cardiac death. In conclusion, in patients with spontaneous non-
sustained ventricular tachycardia: (lj Arrhythmia inducibility varies depending on the underlying heart
disease. Ventricular tachycardia is most often inducible in patients with coronary artery disease and
least often in patients without structural heart disease; (2) With the exception of patients with idiopathic
dilated cardiomyopathy, management of patients with nonsustained ventricular tachycardia guided hy
electrophysiologicaJ testing appears to result in a low incidence of sudden cardiac death although effects
on total mortality are less impressive; and (3) Patients with idiopathic dilated cardiomyopathy and
patients with other heart diseases who continue to have inducible ventricular tachycardia despite antiar-
rhythmic drug therapy are at substantial risk of sudden cardiac death. (PACE. Vol. 16, May, Part 11993)
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Introduction
Nonsustained ventricular taGhycardia is asso-
ciated with an adverse prognosis in certain pa-
tients.'"' Several studies have examined the role
of ejection fraction, Holter monitoring, the signal-
averaged electroGardiogram, and electrophysio-
logical testing in defining prognosis in patients
with nonsustained ventricular tachycardia.'"''
However, the use of these diagnostic tests and the
most appropriate form of therapy in patients with
various types of heart disease and nonsustained
ventricular tachycardia are as yet unclear.
The purpose of this study was to descrihe the
outcome in a large cohort of patients with various
types of heart disease who had nonsustained ven-
tricular tachycardia and whose management was
guided hy electrophysiological testing.
Methods
Patient Population
The present investigation was a retrospective
study of 280 patients consecutive with asymptom-
atic, nonsustained ventricular tachycardia who
underwent electrophysiological testing in the drug
free state. Patients with nonspecific palpitations
were not considered symptomatic for the purposes
of this study. Patients who had suffered a cardiac
arrest or experienced sustained uniform ventricu-
lar tachycardia were not entered into the study.
Nonsustained ventricular tachycardia was defined
as having a duration of three heats to 30 seconds
and was documented by amhulatory monitoring
(240 patients) or telemetry recordings. Seventy-
nine patients had no evidence of structural heart
disease as determined by cardiac catheterization
or the combination of exercise testing and two-
dimensional echocardiography. One hundred thir-
ty-four patients had coronary artery disease docu-
mented by cardiac catheterization or the presence
of a Q wave infarction, and 43 patients had an
idiopathic dilated cardiomyopathy documented
by cardiac catheterization. Twenty-four patients
had other types of heart disease, primarily valvu-
lar heart disease (Table I). One hundred twenty-
five of the 134 patients with coronary disease had
evidence of prior myocardial infarction. Demo-
graphic characteristics of these patients are de-
scribed in Table I.
Electrophysiological Study Protocol
Electrophysiological studies were performed
while patients were fasting and not sedated. In-
formed consent was ohtained from all patients






































































CAD = coronary artery disease; CM = idiopaihic dilated cardiomyopathy: EF - ejection fraction.
* Other Heart Disease: valvular heart disease 13, hypertensive cardiovascular disease 3; idiopathic hypertrophic cardiomyopathy
7; coronary artery spasm 1.
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mic therapy was discontinued at least five half-
lives hefore testing. Three quadripolar catheters
were inserted into a femoral vein and positioned
in the high right atrium, at the right ventricular
apex, and in the right ventricular outflow tract.
Leads VI, 1, and 3 and the intracardiac elec-
trograms were displayed on an oscilloscope and
recorded on a Siemens-Elema Mingograf 7 re-
corder (Siemens-Elema, Solna, Sweden).
Ventricular stimulation was performed using
a programmable stimulator (Bloom Associates,
Narbeth, PA, USA). Rectangular stimuli 2 msec in
duration at twice diastolic threshold were used.
Up to 3 extrastimuli were introduced using at least
two basic drive cycle lengths at the right ventricu-
lar apex and at the right ventricular outflow tract
or upper septum.^ Diastole was scanned as previ-
ously described and coupling intervals were lim-
ited to 200 msec." The endpoint of the stimulation
protocol was the induction of sustained monomor-
phic ventricular tachycardia. Nonsustained poly-
morphic ventricular tachycardia was not an end-
point of the stimulation protocol. If sustained
polymorphic ventricular tachycardia or ventricu-
lar fibrillation was induced once, stimulation gen-
erally was continued in an attempt to induce sus-
tained monomorphic ventricular tachycardia ex-
cept if multiple countershocks were required to
terminate ventricular fibrillation or if the patient
refused further testing.'* Only sustained monomor-
phic ventricular tachycardia was considered a
positive result.
If sustained monomorphic ventricular tachy-
cardia was induced during the haseline electro-
physiological test, the patient underwent serial
drug testing in an attempt to suppress the induc-
tion of ventricular tachycardia. Sustained mono-
morphic ventricular tachycardia was also the end-
point used for assessing drug efficacy. If the induc-
tion of ventricular tachycardia was suppressed by
an antiarrhythmic agent, the patient was treated
long term with that drug. If the induction of ven-
tricular tachycardia was not suppressed hy antiar-
rhythmic therapy, patients were treated with the
drug that made induced ventricular tachycardia
hest tolerated, except for two patients who refused
therapy. Tolerance of ventricular tachycardia was
determined by blood pressure and/or symptoms
during sustained ventricular tachycardia. All pa-
tients who failed drug testing (except one who re-
fused further testing) had undergone at least two
electrophysiological tests on different antiarrhyth-
mic drugs.
The following definitions were used with re-
gard to the electrophysiological study: Sustained
ventricular tachycardia was defined as lasting >
30 seconds or requiring termination because of he-
modynamic compromise. Nonsustained ventricu-
lar tachycardia was defined as lasting from three
beats to 30 seconds. Monomorphic ventricular
tachycardia had a stable QRS morphology when
viewed simultaneously in three leads. Polymor-
phic ventricular tachycardia was defined as hav-
ing a variahle QRS morphology.
Patient Follow-Up
Follow-up information was ohtained from the
patient, patient's family, and/or the patient's phy-
sician. Eleven (3.8%) patients who met the inclu-
sion criteria were lost to follow-up and the remain-
ing 280 patients form the study population. Infor-
mation was obtained on the occurrence of
sustained ventricular tachycardia or cardiac arrest
and on the causes of death.
Deaths were classified as sudden cardiac
death, other cardiac death, and noncardiac death.
For the purposes of this study, sudden cardiac
death was defined as instantaneous death or un-
witnessed death with no evidence of a nonarrhyth-
mic cause of death. Patients who experienced pre-
monitory symptoms consistent with an arrhyth-
mia, e.g., palpitations or presyncope, were also
classified as having sudden cardiac death. The
presence of other premonitory symptoms such as
chest pain or shortness of breath led to a classifica-
tion of "other cardiac death." In three patients,
insufficient information was available to classify
the cause of death. In the analysis of sudden car-
diac death and ventricular tachycardia occur-
rence, these three patients were censored at the
time of death.
Statistical Methods
Data are expressed as mean ± 1 standard de-
viation, Frequencies were compared hy Chi-
square analysis. Survival curves were constructed
using the Kaplan-Meier product limit estimate.^°
The standard errors of survival curves were calcu-
lated using the methods of Kaplan-Meier and mul-
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tiple comparisons between curves were performed
using the Bonferroni correction method.^" A P
value of < 0.05 was considered significant. In ex-
amining outcome, the three response variables
used were the time until sudden cardiac death,
time until death (all causes), and the time until
sustained ventricular tachycardia/ventricular fi-
brillation. Sustained ventricular tachycardia/ven-
tricular fibrillation occurrence was defined as the
occurrence of documented sustained ventricular
tachycardia or sudden cardiac death. The main
goal of the statistical analysis was to assess the
dependence of the three response variables on a
number of explanatory variables. These explana-
tory variables are listed in Table II. The statistical
method used to assess the effect of these explana-
tory variables on survival was Cox regression anal-
ysis. In the first stage of the analysis, each of the
explanatory variables was used to assess its indi-
vidual effect on survival. Explanatory variables
then were combined using a forward selection pro-
cedure to determine the best set of variables re-
lated to survival. Because survival times differ de-
pending on the underlying heart disease, the anal-
ysis was stratified by heart disease. The data were
also separately analyzed for the coronary artery
disease and cardiomyopathy groups. A P value <
0.10 was considered significant for the purpose of
the Cox regression analysis.^"
Instead of selecting a predefined ejection frac-
tion to separate low risk and high risk groups, lo-
gistic regression was used to estimate the probabil-
ity of death as a function of this variable,"' Using
Table II.
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this logistic regression, the sensitivity and speci-
ficity were calculated for different cutoffs of the
predicted probabilities. These predicted probabili-
ties were then inverted to yield the resulting cut-
offs for the ejection fraction.
Results
Electrophysioiogical Testing
Among the 280 patients who underwent a
baseline electrophysioiogical test, 52 (19%) had
inducible sustained monomorphic ventricular
tachycardia. The mean cycle length of monomor-
phic ventricular tachycardia induced during the
baseline electrophysioiogical test was 286 ± 59
msec. A mean of 2.3 ± 0,6 extrastimnli were re-
quired to induce sustained monomorphic ventric-
ular tachycardia. The inducibility of ventricular
tachycardia based on the type of underlying heart
disease is shown in Figure 1. Ventricular tachycar-
dia was induced more frequently in patients with
coronary artery disease (32%] than in the other
groups (P < 0.001). The induction of ventricular
tachycardia in patients with coronary artery dis-
ease was dependent upon the level of left ventricu-
lar function. Nine of 50 (18%) patients with a left
ventricular ejection fraction of > 0.4 had inducible
ventricular tachycardia versus 34 of 84 (40%) pa-
tients with a left ventricular ejection fraction <
0.4 (P < 0.05). Ventricular tachycardia also was
induced more frequently in the patients with idio-
pathic dilated cardiomyopathy (14%) and with
miscellaneous heart diseases (13%) than in those
without structural heart disease (0%; P < 0.01 for
both comparisons). The mean cycle length of in-
duced ventricular tachycardia was similar in the
various heart disease groups: 285 ± 59 msec in
the patients with coronary artery disease, 297 ±
65 msec in the patients with idiopathic dilated car-
diomyopathy, and 280 ± 71 msec in the patients
with miscellaneous heart disease. The mean num-
her of extrastimuli required to induce ventricular
tachycardia was also similar regardless of the un-
derlying heart disease.
Among the 228 patients considered to have
negative electrophysioiogical tests, 156 patients
had no arrhythmia induced, 59 had nonsustained
ventricular tachycardia induced, and 13 had ven-
tricular fibrillation induced.
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' - p<0,001 vs other gps
# - p<0,01 vs CAD and no HD
Figure 1. Inducibility of ventricukir tachycardia according to type o/underlying heorf disease.
The number of patients with inducible monomorphic venfricuiar tachycardia during a baseline
electrophysioiogical test is shown in the solid areas and the number of palieiits without inducibie
sustained ventricuiar (achycardia in the shaded areas, Inducibility of ventricular tachycardia
was highest in the patients with coronary artery disease (CADj, intermediate in those wifh idio-
pathic dilated cardiomyopathy fCM) and miscellaneous heart disease (Misc HD), and lowest in
those without structuraJ heart disease (No HD) (P < 0.01 for pairwise comparisonsj.
Electropharmacoiogical Testing
The patients with inducible sustained mono-
morphic ventricular tachycardia underwent a
mean of 1,9 ± 1.3 drug trials (range 1-5). Three
patients refused electrophysioiogical testing be-
fore having failed at least two antiarrhythmic drug
trials. They were discharged on empiric therapy
(one patient) or no therapy (two patients) and were
considered to have persistently inducible ventric-
ular tachycardia for further analysis. None of these
three patients died suddenly during the follow-up
period. No patient underwent implantation of an
implantable cardioverter defihrillator or had ar-
rhythmia surgery performed.
Among 52 patients who underwent electro-
pharmacological testing, 27 continued to have in-
ducible sustained monomorphic ventricular
tachycardia and 25 did not. During the baseline
electrophysioiogical test, the mean cycle length of
induced ventricular tachycardia (279 ± 59 vs 292
± 59 msec) and the mean number of extrastimuli
needed to induce ventricular tachycardia (2.2 ±
0.7 vs 2.4 ± 0.5) were similar in the patients who
did and did not respond during drug testing. In
the patients with coronary artery disease, five of
nine patients with a left ventricular ejection frac-
tion > 0.4 had the inducihility of ventricular
tachycardia suppressed with antiarrhythmia med-
ication. The patients in whom ventricular tachy-
cardia induction was suppressed hy an antiar-
rhythmic drug wore treated long term with that
drug; the 27 patients who continued to have indu-
cible sustained ventricular tachycardia were dis-
charged on the drug that made the induced ven-
tricular tachycardia slowest and most hemody-
namically stable. Among the 52 patients who had
inducible sustained monomorphic ventricular
tachycardia in the baseline state, two were dis-
charged on no therapy (at the patient's request),
24 received a type IA antiarrhythmic agent, 16 re-
ceived amiodarone, 6 received a combination of
amiodarone and a type I antiarrhythmic agent, and
4 were treated with a type IC antiarrhythmic agent.
Among 228 patients without inducible sus-
tained monomorphic ventricuiar tachycardia dur-
ing the baseline electrophysioiogical test, 89 re-
ceived empiric antiarrhythmic therapy for nonsus-
tained ventricular tachycardia or for atrial
arrhythmias and 139 received no drug therapy.
Forty patients were treated with a type IA antiar-
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rhythmic agent, 11 with amiodarone, 3 with a
comhination of amiodarone and another agent, 10
with verapamil (for nonsustained ventricular
tachycardia in the absence of structural heart dis-
ease), and 25 with a type IC antiarrhythmic agent.
Outcome
Patients were followed for a mean of 19.6 ±
14.4 months (range 1-65). Forty-five of 280 pa-
tients (16.1%) died during the follow-up period.
There were 15 sudden cardiac deaths, 21 nonsud-
den cardiac deaths, 6 noncardiac deaths, and 3
deaths that could not be classified. Survival curves
for deaths from all causes are shown in Figure 2.
Two-year survival was 100% in the patients with-
out heart disease, 83% in the patients with coro-
nary artery disease, 73% in the patients with mis-
cellaneous heart diseases, and 68% in the patients
with idiopathic dilated cardiomyopathy. The
probability of survival was significantly higher in
the patients without structural heart disease (P <
0.01) than in all the other groups. In addition, pa-
tients with coronary artery disease had a signifi-
cantly lower mortality than those with idiopathic
dilated cardiomyopathy (P < 0.05),
The incidence of sudden cardiac death at 2
years was 0% in the patients without heart disease,
5% in the patients with coronary artery disease,
4% in the patients with miscellaneous heart dis-
eases, and 23% in the patients with idiopathic di-
lated cardiomyopathy. Patients without structural
beart disease had a significantly lower incidence
of sudden cardiac death than all other groups (P <
0,01) and the patients with coronary artery disease
had a lower incidence than patients with idio-
pathic dilated cardiomyopathy (P < 0.02). How-
ever, patients with idiopathic dilated cardiomyop-
athy had a mean ejection fraction that was lower
than that in the other groups (Table I).
Survival curves for freedom from sudden car-
diac death are shown in Figure 3. Four of the 52
patients with inducible sustained ventricular
tachycardia during the baseline electrophysiologi-
cal test died suddenly during the follow-up pe-
riod. The mean cycle length of induced ventricular
tachycardia was 305 ± 86 msec in the foiir pa-
tients who died suddenly and 284 ± 57 msec in
the 48 patients who did not die suddenly (NS).
The number of extrastimuli required to induce
ventricular tachycardia was also similar in these
two groups (2.2 ± 0.5 extrastimuli vs 2.3 ± 0.6
extrastimuli).
Twenty-four of 280 patients either died sud-
denly or had an episode of sustained ventricular
tachycardia during follow-up. One had no under-
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Figure 2. Survival curve analysis
^j total mortality during follow-up
in each of the subgroups. Total
mortality was highest in the pa-
tients with idiopathic dilated car-
diomyopalhy, intermediate in
those with coronary artery disease
and miscellaneous heart disease,
and lowest in those without struc-
tural heart disease. See text/or de-
tails.
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Figure 3. Sudden cardiac death in
each of the subgroup.s. The inci-
dence of sudden cardiac death was
highest in patients with idiopathic
dilated cardiomyopathy, interme-
diate in patienfs with coronary ar-
tery diseases and misceJJaneous
heart disease, and lowest in pa-
tients without StructuraJ heart dis-
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lying heart disease, 13 had coronary artery disease,
8 had an idiopathic dilated cardiomyopathy, and
2 had miscellaneous heart diseases. Freedom from
sustained ventricular arrhj^hmia occurrence in
each of the groups is shown in Figure 4. Patients
without structural heart disease were less likely
to experience a sustained arrhythmia occurrence
during follow-up than were patients with coronary
artery disease or idiopathic dilated cardiomyope-
thy (P < 0.05].
Figures 5 through 7 describe patient outcome
based on the results of electrophysioiogical test-
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Figure 4. Survival curve analysis
of freedom from arrhythmia recur-
rence in each of the subgroups,
VentricuJar tachycardia and sud-
den cardiac death were highest in
patients with idiopathic diJated
cardiomyopathy, intermediate in
(hose wilh coronary artery disease
and miscelJaneous heart diseases,
and lowest in those without struc-
tural heart disease. See text/or de-
tails.
























Figure 5. ReJationship of results of eJectrophysioJogicaJ testing to outcome in the totaJ group
of 280 patients.
ing. Frequency data [not actuarial survival) is pre-
sented in the figures for simplicity. The relation-
ship between the results of electrophysioiogical
testing and outcome for all patients is shown in
Figure 5. Patients who had inducihle ventricular
tachycardia during the predischarge electrophysi-
oiogical test had the highest actuarial incidence of
sudden cardiac death during follow-up (11% at 2
years]. The incidence of sudden cardiac death at
2 years was 0% in the patients treated with an anti-
arrhythmic agent that suppressed the induction of



























Figure 6. Relationship of the results of eiectrophysioJogical testing to outcome in 134 patients
with coronary artery disease.
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Figure 7. Relationship of the results of electrophysioiogicai testing to outcome in 43 patients
wilh idiopathic dilated cardiomyopathy.
empirically with antiarrhythmic agents despite
negative baseline electrophysiological tests, and
5% in the untreated patients. Data on the 134 pa-
tients with coronary artery disease and on the 43
patients with idiopathic dilated cardiomyopathy
are shown in Figures 6 and 7. Patients with idio-
pathic dilated cardiomyopathy were at high risk
for sudden cardiac death despite a negative elec-
trophysiological test. If patients with idiopathic
dilated cardiomyopathy are excluded from the
analysis, the incidence of sudden cardiac death at
1 year was 0% in the 22 patients who were treated
with drugs that were effective in suppressing in-
ducible ventricular tachycardia, 12% in the 24 pa-
tients who did not have inducible ventricular
tachycardia suppressed at electrophysiological
testing, and 3% in the 191 patients with a negative
baseline electrophysioiogicai test. The incidence
of sudden death was not significantly different in
those who did (2.6%) versus did not (3.4%) receive
empiric therapy.
Predictors of Outcome
Results of the forward selection procedure are
shown in Table III.
Using the forward selection procedure, only
lower ejection fraction and inducible ventricular
tachycardia during the predischarge electrophysi-
ological test correlated with sudden death during
follow-up. Older age. lower ejection fraction, and
higher New York Heart Association (NYHA] clas-
sification all correlated with total mortality during
the follow-up period. Sustained ventricular ar-
rhythmia occurrence during the follow-up period
was associated with a lower ejection fraction and
inducible sustained ventricular tachycardia dur-
ing the predischarge electrophysiological test.
Survival analysis was repeated in two
subgroups: patients with coronary artery disease
and patients with idiopathic dilated cardiomyopa-
thy. Despite the high percentage of sudden cardiac
death in patients with idiopathic dilated cardio-
myopathy, the number of patients was too small
to perform the forward selection procedure. In pa-
tients with coronary artery disease, increasing age,
lower ejection fraction, and higher NYHA classifi-
cation correlated with sudden cardiac death. In-
creasing age, higher NYHA classification, and ven-
tricular tachycardia induced during the predis-
charge electrophysiological test correlated with
total mortality. No variables correlated with sus-
tained ventricular arrhythmia occurrence in the
patients with coronary artery disease.
Using logistic regression, a left ventricular
ejection fraction of 0.37 provided the best discrim-
ination among outcomes [Fig. 8). Patients who had
an ejection fraction > 0.37 had a 0% incidence of
sudden cardiac death at 2 years, whereas those
who had an ejection fraction < 0.37 had a 25%
incidence of sudden cardiac death at 2 years (P <
0,001). In addition, patients with a left ventricular
ejection fraction < 0.37 who had coronary artery














































EF = ejection fraction; NYHA = New York Heart Association Class; VT last Dx = Inducible VT at predischarge electrophysiologi-
cat testing.
disease or miscellaneous heart disease and a nega-
tive baseline electrophysiological test had a 2-year
sudden cardiac death mortality of only 6%.
Survival analysis was repeated to determine
the relationship between therapy with specific
antiarrhythmic agents and subsequent arrhythmia
events. By univariate analysis, therapy with type
IA, IC, or III antiarrhythmic agents was not associ-




The major finding of this study is that the use
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Figure 8. Freedom from sudden
cardiac death in the totaJ patient
population stratified by ejection
fraction (EF). An EF of 0.37 had a
sensitivity of 93% and a specificity
of 59% in predicting sudden car-
diac death.
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cological testing to manage patients with nonsus-
tained ventricular tachycardia are associated with
a low incidence of sudden cardiac death in pa-
tients with coronary artery disease, miscellaneous
heart diseases, and in patients without structural
heart disease. However, the incidence of sudden
death in patients with idiopathic dilated cardio-
myopathy was high [17% at 1 year). The results
suggest that electrophysiologicai testing and elec-
tropharmacological therapy may be useful in man-
aging patients with heart diseases other than idio-
pathic dilated cardiomyopathy. Excluding those
who had idiopathic dilated cardiomyopathy, pa-
tients with negative baseline electrophysiological
tests or those treated with antiarrhythmic drugs
that suppressed the induction of ventricular tachy-
cardia had a low incidence of sudden cardiac
death during follow-up. In contrast, patients with
persistently inducible ventricular tachycardia and
patients with idiopathic dilated cardiomyopathy
remained at substantial risk of sudden cardiac
death. However, the results of this study must be
regarded as preliminary because of the potential
for proarrhythmia in the patients treated empiri-
cally and because total mortality was not clearly
related to the results of electropbysiological
testing.
Effect of Underlying Heart Disease
Sudden cardiac death and total mortality ap-
peared to be dependent on the underlying heart
disease in this study. Patients without structural
heart disease had a negligible incidence of ventric-
ular tachycardia or death during follow-up. Pa-
tients with coronary artery disease and miscella-
neous heart diseases had a moderately low mortal-
ity from sudden cardiac death, whereas patients
with idiopathic dilated cardiomyopathy had a
high mortality from sudden and nonsudden car-
diac death. However, patients with idiopathic di-
lated cardiomyopathy had lower left ventricular
ejection fractions than tbose in other groups and
thus the independent risk of the type of underlying
heart disease on outcome cannot be established
with certainty.
Electrophysiological testing was not of value
in patients without structural heart disease who
had asymptomatic nonsustained ventricular
tachycardia, electrophysiological tests were uni-
formly negative and prognosis was excellent. In
addition, an ejection fraction > 0.37 was associ-
ated with a good prognosis in all groups of patients
when patients were managed based on the results
of electrophysiological testing. However, the use
of this number as an absolute cutoff for assessing
risk must be approached with caution, because the
number was retrospectively derived.
The results of this study suggest that electro-
physiological testing may be of benefit in risk strat-
ification and management of patients with coro-
nary artery disease or miscellaneous heart disease
and left ventricular dysfunction. The inducibility
of ventricular tachycardia during the predischarge
electrophysiological test was an independent pre-
dictor of sudden cardiac death. The value of a neg-
ative baseline electrophysiological test in this
group of patients cannot be determined witb cer-
tainty in the absence of a control group not sub-
jected to electrophysiological testing. However,
this incidence of sudden death of 2% per year is
lower than in several groups of historical controls
with untreated spontaneous nonsustained ventric-
ular tachycardia.^ ' When the analysis was con-
fined only to patients with coronary artery disease,
the raw incidence of sudden cardiac death was
lower in patients with negative predischarge elec-
trophysiological tests than those with positive
ones [6% vs 14%), but this difference did not reach
significance perhaps because of the smaller num-
ber of patients. A positive electrophysiological test
also appeared to be of value. Patients with a posi-
tive baseline electrophysiological test in whom
ventricular tachycardia was suppressed by antiar-
rhythmic therapy had a 0% incidence of sudden
cardiac death whereas those with persistently in-
ducible ventricular tachycardia had a 20% inci-
dence of sudden cardiac death at 2 years, suggest-
ing that the results of electropharmacological test-
ing are predictive of outcome in these patients. In
patients with idiopathic dilated cardiomyopathy,
a negative electrophysiological study had no pre-
dictive value. Six of 37 patients with a negative
electrophysiological test died suddenly during fol-
low-up. However, it is possible that a positive elec-
trophysiological test was useful in these patients.
Although none of the three patients with a positive
baseline electrophysiological test who had ven-
tricular tachycardia suppressed by antiarrhythmic
medications experienced sudden cardiac death or
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ventricular tachycardia during follow-up, this
number of patients clearly is too small to allow
any conclusions.
Results of Prior Studies
The results of several prior studies that in-
cluded relatively small numbers of patients have
been divergent. Some studies have suggested that
electrophysiological studies are of no value in risk
stratification or patient management, while others
have suggested that the noninducibility of ventric-
ular tachycardia predicts a low incidence of sud-
den death.^^"^^ The majority of studies have con-
cluded that the inducibility of sustained ventricu-
lar tachycardia portends a poor prognosis.**'̂ '*'̂
Three recent studies of 100 or more patients
have examined the value of electrophysiological
testing in patients with nonsustained ventricular
tachycardia. Hammill et al.'^ studied 110 patients
with a variety of types of heart disease, and fol-
lowed them for a mean of 15 months. In their
study, only the ejection fraction and the presence
of congestive heart failure were independent pre-
dictors of outcome, and electrophysiological test-
ing was not of major benefit in risk stratification.
Kowey et al.̂ ^ studied 205 asvmptomatic patients
with coronary disease and remote myocardial in-
farction. Only left ventricular function correlated
significantly with outcome and electrophysiologi-
cal testing did not appear to be of major value.
Unexpectedly, 14 of 45 patients (31%) had ventric-
ular tachycardia or sudden cardiac death despite
receiving therapy guided by electropharmacologi-
cal testing.^^ This incidence of ventricular tachy-
cardia and sudden death is inexplicably higher
than noted in historical controls who presented
with sustained ventricular tachycardia.^"* Wilber
et al."* reported the results of electrophysiological
testing in 100 consecutive patieuts with ejection
fractions of < 0.40, spontaneous nonsustaiued
ventricular tachycardia, and prior myocardial in-
farction. The persistence of inducible sustained
ventricular tachycardia was the only independent
predictor of sudden cardiac death in that study.
Prior studies have suggested that electrophys-
iological testing is uot useful in managing patients
with idiopathic dilated cardiomyopathy.^"'^^ Pa-
tients with negative electrophysiological tests had
a high risk of sudden cardiac death in studies by
Kron et al.^° and Das et al.̂ ^ The results of the
present study are in agreement with these find-
ings. One potential complicating feature in inter-
preting the results iu patients with dilated cardio-
myopathy is that a recent study has suggested that
bradycardia may be a common mechanisru of sud-
den cardiac death in such patients.^^ Thus, diag-
nostic tests and therapeutic maneuvers directed at
tachyarrhythmias may be less beneficial iu such
patients.
The reasons for the different findings in this
study compared to some other recent studies are
unclear. The major difference between this study
and the study of Kowey et al.^^ is the low inci-
dence of sudden cardiac death in this study in pa-
tieuts who received antiarrhythmic therapy
guided by electrophysiological testing. This low
incidence is similar to that described by Klein and
MachelP^ and by Wilber et al.'" One potential ex-
planation is that iu the multicenter study by
Kowey et al.,'^ there may have been differences in
the endpoints of electropharmacological testing.
The role of electropharmacological testing in the
management of patients who present with sus-
tained tachyarrhythmias is also somewhat contro-
versial. Although a large number of studies (re-
viewed in reference 23) have suggested that
suppression of inducible sustained ventricular
tachycardia by type I antiarrhythmic drugs por-
tends a good prognosis, recent studies such as
those by Poole et al.^^ suggests that this may not
be true. However, in the present study, patients
presenting with nousustained ventricular tachy-
cardia who had inducible ventricular tachycardia
suppressed by autiarrhythmic drugs had a 0% in-
cidence of sudden cardiac death at 2 years.
The findings of this study are generally in
agreement with those of Wilber et al.^^ However,
there are two important differences between the
two studies aside from the larger number of pa-
tients in the present study. Rather than selecting
a predefined ejection fraction for inclusion iu the
study, we analyzed data from all patients and per-
formed logistic regression prospectively to define
an ejection fraction (0.37) that provided an excel-
lent separation between patients with and without
subsequent cardiac death. In addition, we in-
cluded all patients regardless of the nature of the
underlying heart disease, allowing a comparison
among different heart disease groups.
In contrast to the findings of the CAST
study,^^ therapy with antiarrhythmic drugs in gen-
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eral and with type IC antiarrhythmic drugs in par-
ticular did not correlate with the occurrence of
sudden cardiac death or ventricular tachycardia.
One potential explanation is that in the present
study these drugs were used empirically only in
patients with negative electrophysiological stud-
ies. It is possible that patients with inducible ven-
tricular tachycardia are at bigher risk of proar-
rhythmia from type IC antiarrhythmic agents. In
addition, a number of patients who received type
IC antiarrhythmic agents in this study had normal
left ventricular function and tbis also may have
contributed to lowering tbe risk of a proarrhyth-
mic response to antiarrhythmic drugs.
Limitations
The major limitation of this study is the ab-
sence of an untreated or placebo control group.
Therefore, it cannot be proven that management
based on the results of electrophysiological testing
improved the outcome in patients who had indu-
cible ventricular tachycardia. The response of in-
ducible ventricular tachycardia to antiarrhythmic
drugs may itself be a marker of good outcome. Al-
though comparison with historical controls^"^
suggests that the incidence of sudden cardiac
death in patients in this study who had inducible
ventricular tachycardia was low, such retrospec-
tive comparisons have major limitations. A second
limitation of this study is that 11 patients were
lost to follow-up and that the mechanism of deaths
could not be determined with certainty in three
patients. However, this represents a low percent-
age of the total number of patients in the study
(3.8%) and of total deaths (6.3%) and thus any
error introduced into the study by missing data
should be small. In addition, 89 of 228 patients
with a negative baseline electrophysiological test
were treated with antiarrhythmic drugs by their
referring physicians. However, drug therapy was
not an independent predictor of subsequent events
in the study and the incidence of sudden cardiac
death was similar in the patients who received em-
piric drug therapy and those who did not. Another
limitation of this study is the small number of pa-
tients in the group with miscellaneous heart dis-
ease. In addition, patients in this group contained
various diagnoses including hypertrophic cardio-
myopathy and valvular heart disease. Although
these patients were included in the study so that
consecutive patients could be reported, the num-
bers are probably too small to draw any meaning-
ful conclusions. In addition, we did not analyze
the occurrence of sustained ventricular tachycar-
dia alone as a separate outcome but only in combi-
nation with cardiac arrest. This was done to limit
the number of statistical analyses. Finally, the re-
sponse rate to antiarrhythmic drugs in this study
was unusually high. This may have in part been
secondary to the fact tbat inducible nonsustained
ventricular tachycardia [< 30 sec] was considered
a drug success. This unusually high response rate
may limit the applicability of these results to other
patient populations.
Clinical Implications
The results of this study must be regarded as
preliminary because of the absence of a control
group and because of the small number of patients
in some subgroups. However, they suggest that
electrophysiological testing may be of benefit in
risk stratification and management of some pa-
tients with nonsustained ventricular tachycardia
depending on left ventricular function and the
type of heart disease. Among patients who have
left ventricular dysfunction, those with coronary
artery disease or miscellaneous heart diseases and
a negative electrophysiological test had a low inci-
dence of sudden cardiac death and may not re-
quire antiarrhythmic drug therapy. Patients who
have a positive baseline electrophysiological test
and in whom the induction of ventricular tachy-
cardia is suppressed by antiarrhythmic drugs also
had a low incidence of sudden cardiac death, and
electropharmacological testing may be a useful
guide to therapy. However, patients who have a
positive electrophysiological test and in whom the
induction of ventricular tachycardia cannot be
suppressed by antiarrhythmic drugs have a high
incidence of sudden death as do patients with id-
iopathic dilated cardiomyopathy regardless of the
results of electrophysiological testing. These pa-
tients therefore may be appropriate candidates for
nonpharmacological therapy, such as placement
of an implantable cardioverter defibrillator. The
risk to benefit ratio of device implantation or other
therapy in these types of patients remains to be
determined by larger clinical trials using placebo
controls.
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